JUN 24, 2019 8:27 AM PDT

New Drug Target for Chemically-Induced Parkinson Disease

WRITTEN BY: Nouran Amin

Once upon a time, a compound found in synthetic opioid, MPTP induced the onset of Parkinson's disease. Early studies show that MPTP induces Parkinson disease in rodents and primates. The most recent study indicates that a naturally-occurring enzyme, known as mitochondrial CYP2D6, can metabolize certain compounds into MPTP-like chemicals and trigger Parkinson in mouse studies. Now, researchers are proposing a new treatment for chemically-induced Parkinson via targeting the mitochondrial CYP2D6 enzyme.

PennToday: Findings from Penn Vet suggest a potential new target for treating Parkinson’s, an enzyme that wreaks its damage on dopamine-producing neurons. Credit: PennToday.UPenn.edu

"Over the past two or three decades, researchers have tried inhibiting the process by which they believed MPTP was metabolized, with mixed success," says research leader, Narayan Avadhani. "We believe that mitochondrial CYP2D6 is the more direct drug target, which might prove better in treating idiopathic Parkinson's disease."

Learn more about Parkinson Disease:

Findings of the study were published in the Journal of Biological Chemistry and investigates the mechanism of Parkinson's disease with unknown causes. Current mechanism of action is believed to involve the oxidation of compounds to form MPP+--a toxic metabolite thought to be transferrable to dopamine neurons via dopamine transporter proteins. The process seemed logical since Parkinson disease is characterized by unusually low dopamine levels in the brain.

PennToday: The new model overturns a current paradigm of how chemical insults lead to Parkinson’s disease. (Image: Avadhani lab)

Targeting the mechanism of action, researchers showed that mice lacking CYP2D6 did not present with any severe symptoms that mice with the protein did. Furthermore, a CYP2D6 inhibitor was seen to prevent neuronal damage in mice.

"CYP2D6 is known to play a role in influencing the activity of a number of drugs," says Avadhani. "The CYP2D6 inhibitor ajmalicine is a member of the reserpine family of alkaloids, found in the plant Rauwolfia serpentine and was long used in India for treating mental illness, such as paranoia and schizophrenia. Mitochondrial targeting of such compounds is likely to be effective in treating Parkinson's patients, and pursuing that is our future strategy."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
AUG 05, 2021
Cannabis Sciences
Brain's Version of THC Reduces Seizures, Increases Side Effects
AUG 05, 2021
Brain's Version of THC Reduces Seizures, Increases Side Effects
An endocannabinoid similar to tetrahydrocannabinol (THC) that naturally occurs in the brain reduces seizure activity. Ho ...
AUG 08, 2021
Microbiology
Manganese Could be an Achilles' Heel for Some Pneumonia Germs
AUG 08, 2021
Manganese Could be an Achilles' Heel for Some Pneumonia Germs
Researchers recently discovered bacteria that fed on the element manganese. Scientists also know that some bacterial pat ...
AUG 19, 2021
Cancer
Japanese Berry Vine Could Treat Lung Cancer
AUG 19, 2021
Japanese Berry Vine Could Treat Lung Cancer
A berry-producing vine in Japan has shown promise in mouse models for treating lung cancer. The corresponding study was ...
AUG 20, 2021
Cannabis Sciences
Teenage Cannabis Use Linked to Preterm Births in Adulthood
AUG 20, 2021
Teenage Cannabis Use Linked to Preterm Births in Adulthood
People who heavily used cannabis in their teens are more likely to have premature babies than those who did not use the ...
AUG 20, 2021
Health & Medicine
Nanotechnology and Management of COVID-19- A Promising Future?
AUG 20, 2021
Nanotechnology and Management of COVID-19- A Promising Future?
The rate of viral spread and high mortality demanded a quick response to COVID-19.  As such, pre-existing drugs wer ...
SEP 14, 2021
Health & Medicine
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
SEP 14, 2021
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
As treatments and infection control practices surrounding COVID-19 continue to evolve, nanotechnological solutions are b ...
Loading Comments...